SLC5A2 and diabetes mellitus: Treatment for diabetes and NASH with a combination of pioglitazone and either a GLP-1 receptor agonist or SGLT-2 inhibitor may be a cost-effective strategy while lowering the increased cardiovascular risks in this patient population (94).